Milestones and Patents

Milestones

Lessons learned by study at the retrovirus-host interface

  • Milestones
    Patented retroviral structural gene vectors
  • Discovered translation control mechanism conferred by retroviruses
  • Elucidated the cellular effector protein and cognate cis-acting responsive elements in the 5' UTR
  • Solved the secondary structure of the cognate viral RNA element and cellular paralog
  • Defined the molecular basis is DHX9/RNA helicase tethered to cognate viral and cellular mRNAs
  • Quantified DICER suppresses synthesis of HIV-1 virion proteins
  • Defined HIV-1 antagonizes DICER activity and requires the arginine-rich RNA binding domain in Tat
  • Revealed HIV-1 downregulates host protein synthesis due to activating eIF4E inhibitory binding protein
  • Characterized Vpr is necessary and sufficient for downregulation of host translation
  • Discovered the retention of nuclear cap-binding protein provides HIV-1 resistance to eIF4E inhibition
  • Distinguished distinct components of HIV-1 RNPs for protein synthesis and virion biogenesis
  • Revealed unique capacity for reinitiation of translation by the translation RNP of human retroviruses
  • Defined specific nuclear interactions that distinguish a viral RNP for virion biogenesis
  • By usurping the cell’s gene expression machineries, retroviruses produce a dozen gene products from a single RNA.
  • Distinctions in the viral RNPs are expected to reveal selectivity to pulling its Achilles' heel.

Patents

  1. US 5554524 A: More complex type retroviruses having mixed type LTR, and uses thereof
  2. US 5770428 A: Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribosome entry site

Animal Science Veterinary Medicine (AS/VM) Building

Location